cetuximab,afatinib,pembrolizumab,adagrasib
mirati,eli lilly,boehringer ingelheim,merck
['adagrasib', 'cetuximab', 'krystal-1', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
our expert will give a very interesting talk at #esmo2022. #krystal-1: updated efficacy and safety of #adagrasib w/ or w/o #cetuximab in advanced #crc with krasg12c mutation! 12/09/2022, 1015 7.2.f f camp auditorium #meded 
Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB